Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene Therapeutics Reports First Quarter 2020 Financial Results
11:30am, Wednesday, 06'th May 2020
Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology.
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
12:00am, Wednesday, 06'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
03:45pm, Tuesday, 05'th May 2020
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
03:40pm, Tuesday, 05'th May 2020
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Why Earnings Season Could Be Great for Allogene Therapeutics (ALLO)
12:43pm, Tuesday, 05'th May 2020
Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Allogene Therapeutics Inc (NASDAQ:ALLO) Short Interest Update
08:46am, Friday, 01'st May 2020
Allogene Therapeutics Inc (NASDAQ:ALLO) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 14,110,000 shares, a growth of 6.9% from the March 31s
-$0.57 Earnings Per Share Expected for Allogene Therapeutics Inc (NASDAQ:ALLO) This Quarter
07:02am, Friday, 01'st May 2020
Equities analysts forecast that Allogene Therapeutics Inc (NASDAQ:ALLO) will announce ($0.57) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero anal
Allogene Therapeutics (ALLO) Gets a Buy Rating from Canaccord Genuity
10:31am, Thursday, 30'th Apr 2020
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Allogene Therapeutics (ALLO), with a price target of $36.00.
Allogene Therapeutics (ALLO) Gets a Buy Rating from Canaccord Genuity
10:31am, Thursday, 30'th Apr 2020
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Allogene Therapeutics (ALLO – Research
Is a Beat in Store for Amarin (AMRN) This Earnings Season?
03:54pm, Wednesday, 29'th Apr 2020
Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Is a Beat in Store for Amarin (AMRN) This Earnings Season?
03:54pm, Wednesday, 29'th Apr 2020
Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Oral Presentation is the First Data Readout from this Dose Escalation Study of ALLO-501, an Allogeneic Anti-CD19 CAR T TherapyALPHA Study Utilizes ALLO-647 Administered as Part.
Company Developed TurboCAR™ Technology Allows Cytokine Activation Signaling to be Engineered Selectively into CAR T CellsPreclinical Studies Provide Evidence That Cytokine.
What's in Store for Innoviva (INVA) This Earnings Season?
03:58pm, Tuesday, 28'th Apr 2020
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.
